The company posted stronger third-quarter profit margins, driven by growth in its electrophysiology and WATCHMAN product lines, which improved the overall product mix despite tariff pressures. Furthermore, a recent decision by the Centers for Medicare & Medicaid Services to extend reimbursement for cardiac catheter ablation to ambulatory surgery centers is expected to increase procedure volumes. This regulatory change is anticipated to benefit the company alongside other major medical device makers, providing a tailwind for future sales in its key cardiovascular segments.